Patents Assigned to THE JOHNS HOPKINS UNIVERSTY
  • Methods for making giant vesicles and their use
    Patent number: 11951210
    Abstract: This application is directed to methods which allow for encapsulation of an array of biological materials under physiological conditions that are relevant given a biological context and the compositions made using those methods. These reconstituted biological materials encompass: a) purified proteins that can bind to the lipid membranes inside and outside of vesicles based on the electrostatic charge; b) purified cytosolic proteins that position themselves in the lumen of the vesicles, c) mammalian cell extracts with an array of cytosolic protein content, among other contents and d) small biological molecules such as DNA and RNA as well as fluorescent dyes/probes. These vesicles can be used to simulate cells in drug discovery methods as well as useful in administering drugs and other compositions to cells in vitro and in vivo.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: April 9, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Shiva Razavi, Takanari Inoue, Tianzhi Luo, Douglas Robinson
  • Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
    Patent number: 11932664
    Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: March 19, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Marcela Krecmerova, Tomas Tichy, Pavel Majer, Andrej Jancarik
  • Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
    Patent number: 11911488
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 27, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
  • Oxazolidinone for treatment of infections with
    Patent number: 11896584
    Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: February 13, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, UNIVERSITY OF ST. THOMAS
    Inventors: Gyanu Lamichhane, J. Thomas Ippoliti
  • Prodrugs of hydroxamate-based GCPII inhibitors
    Patent number: 11866394
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 9, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I.
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [F]DCFPYL
    Patent number: 11851407
    Abstract: Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: December 26, 2023
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Hayden T. Ravert, Daniel P. Holt, Ying Chen, Ronnie C. Mease, Hong Fan, Martin G. Pomper, Robert F. Dannals